CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 31,460	$ 63,458
Marketable securities	31,484	5,993
Accounts receivable - related party	373	507
Prepaid and other current assets	1,050	1,354
Total current assets	64,367	71,312
Property and equipment, net	364	451
Operating lease right-of-use asset	2,952	3,190
Investment in Angel Pharmaceuticals	33,371	34,266
Other assets	236	236
Total assets	101,290	109,455
Current liabilities:
Accounts payable	2,189	1,565
Operating lease liability	1,090	1,046
Accrued and other liabilities	5,986	7,081
Total current liabilities	9,265	9,692
Operating lease liability	2,303	2,601
Total liabilities	11,568	12,293
Commitments and contingencies (Note 13)
Stockholders' equity:
Preferred stock: $0.0001 par value; 10,000,000 shares authorized at March 31, 2022 and December 31, 2021; 0 shares issued and outstanding at March 31, 2022 and December 31, 2021
Common stock: $0.0001 par value; 290,000,000 shares authorized at March 31, 2022 and December 31, 2021; 46,553,511 and 46,553,511 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively	5	5
Additional paid-in capital	362,408	361,669
Accumulated other comprehensive (loss) income	1,987	1,869
Accumulated deficit	(274,678)	(266,381)
Total stockholders' equity	89,722	97,162
Total liabilities and stockholders' equity	$ 101,290	$ 109,455